EBR Systems Opens $85.6 Million Retail Entitlement Offer to Boost US Growth

EBR Systems Launches Retail Entitlement Offer

EBR Systems (ASX:EBR), the Silicon Valley medtech innovator behind the world’s only wireless endocardial pacing system, has opened its retail entitlement offer to raise approximately AUD 43.6 million. This retail tranche forms part of a broader capital raising targeting AUD 85.6 million through a 1-for-2 accelerated non-renounceable entitlement offer priced at $0.38 per new CHESS Depositary Interest (CDI). The offer is fully underwritten by Canaccord Genuity, Morgans Corporate, and E&P Capital.

The retail offer opened on 11 June 2026 and is scheduled to close on 22 June 2026, inviting eligible securityholders in Australia and New Zealand to participate. Fractional entitlements will be rounded down, and entitlements are non-transferable, meaning investors who do not participate will face dilution.

Capital Raise Complements Institutional Placement

The entitlement offer follows a successfully completed institutional placement and institutional entitlement offer announced earlier in June, which collectively raised AUD 106.4 million. The institutional component included a $29.4 million tranche placed without shareholder approval and a conditional $35 million tranche subject to securityholder approval expected in August 2026. Combined with the retail offer, EBR aims to raise a total of approximately $150 million before costs.

This capital injection is earmarked to accelerate the commercialisation and manufacturing scale-up of EBR’s WiSE® Cardiac Resynchronisation Therapy (CRT) system, supporting sales force expansion, manufacturing tooling, research and development, and general working capital needs. The WiSE system, which eliminates the need for traditional pacing leads, has gained traction with 41 implants completed in Q1 2026 and major purchasing agreements signed with US hospital networks including HCA Healthcare, Advocate Health, and CHRISTUS Health.

Offer Pricing and Market Impact

The offer price of $0.38 per new CDI represents a 19.1% discount to the last close price before the offer announcement and an 11.2% discount to the theoretical ex-rights price. This pricing aims to incentivise participation amid ongoing dilution, as the new securities will represent approximately 87.6% of existing CDIs on issue post-offer.

New CDIs will rank equally with existing securities and are subject to US securities laws, including a six-month distribution compliance period restricting resale to US persons. To enforce these restrictions, the CDIs will carry a “FOR US” designation on ASX, preventing sales to US persons during the compliance period.

Investor Considerations and Risks

EBR’s retail offer booklet outlines detailed application procedures, eligibility criteria, and risks associated with investing in an early-stage medical device company. Key risks include market acceptance of the WiSE system, regulatory approvals, manufacturing scale-up challenges, and competitive pressures. Investors are advised to consult professional advisers before participating.

The company’s commercial momentum is underpinned by FDA approval, premium Medicare reimbursement, and a growing US sales footprint. However, EBR remains unprofitable and is investing heavily in infrastructure and sales expansion to reach cash flow breakeven.

With the retail offer now live, the market will be watching subscription levels closely, especially given the conditional nature of the $35 million tranche awaiting shareholder approval. The proceeds will be critical to sustaining EBR’s ambitious US commercial rollout and manufacturing transition to a new Santa Clara facility by year-end.